Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9

Sponsor
General Hospital of Shenyang Military Region
Study ID
NCT07652203
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cirrhosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • conventional therapy — OTHER
    Conventional treatment of decompensated cirrhosis mainly includes anti-hepatic fibrosis drugs, albumin infusion, diuretics, peritoneal drainage, esophageal variceal ligation, endoscopic tissue adhesive injection, blood purification, and liver transplantation.
  • propranolol — DRUG
    Propranolol will be started with 10-20 mg/day for the propranolol group, which will be gradually increased to the maximum tolerance dosage or achieve a heart rate of 55-60 beats per minute and a systolic blood pressure of 90mmHg.

Study Details

Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease. Emerging evidence suggests that NSBBs may worsen the prognosis of advanced cirrhosis, especially in patients with a model for end-stage liver disease (MELD) score of \>9. The purpose of this randomized controlled trial is to evaluate the effects of the use of propranolol as recommended by the guideline on the prognosis in cirrhotic patients with a MELD score of \>9.

Key Dates

First listed
Jun 16, 2026
Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2028

Study Design

Enrollment
466 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Conventional treatment without propranolol
    Patients are provided with conventional supportive treatment only, but without nonselective beta blockers.
  • Active Comparator: Conventional treatment combined with propranolol
    Patients are administered with propranolol in addition to conventional treatment.

Primary Outcome Measure

The time from randomization to the occurrence of further decompensation [ Time Frame: Time to first further decompensation event, assessed from randomization up to the end of the study (maximum of approximately 96 weeks) ]

Central Contacts

Related Studies